Skip to Main Content

INFORMATION FOR

Project NEW HOPE

Project NEW HOPE was a double-blinded placebo controlled RCT of XR NTX among HIV+ prisoners with opioid dependence who were transitioning from the prison to the community setting. HIV treatment (HIV-1 RNA levels, CD4 count), substance abuse treatment (time to relapse to opioid use, percent of days using opioids, percent of days abstinent from opioids, addiction severity), adverse side effects, and HIV risk behavior (sexual and drug-related risks) outcomes were assessed. This project was conducted in New Haven, Hartford, and Springfield in collaboration with Baystate Medical Center.

Funding provided by:
National Institute on Drug Abuse 

Project Period:
September 1, 2010 – August 31, 2015 

Link to Report:
Project New Hope at projectreporter.nih.gov

  • Principal Investigator

    Associate Professor of Medicine (AIDS) and Associate Clinical Professor of Nursing; Director, Infectious Disease Outpatient Clinic, Veterans Administration Healthcare Services, Newington

    Sandra Springer, MD is an Associate Professor of Medicine in the Department of Internal Medicine, Section of Infectious Diseases at the Yale School of Medicine. Dr. Springer is Board-Certified in Internal Medicine, Infectious Diseases and Addiction Medicine. In addition, she is an attending physician at the Veterans Administration Connecticut Healthcare System (VACHS) and the Director of the Infectious Disease Clinic at the Newington site of the VACHS. She graduated from Harvard University, then later received her Medical Degree from University of Massachusetts Medical School. She did her Internal Medicine Residency and Infectious Disease Fellowship at Yale School of Medicine. She currently is the director of her clinical research lab InSTRIDE (Integrating Substance use Treatment Research with Infectious Disease for Everyone) https://medicine.yale.edu/lab/springer/